Ratiometric delivery of doxorubicin and berberine by liposome enables superior therapeutic index than DoxilⓇ
Open Access
- 1 May 2020
- journal article
- research article
- Published by Elsevier in Asian Journal of Pharmaceutical Sciences
- Vol. 15 (3) , 385-396
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Berberine Inhibits Doxorubicin-Triggered Cardiomyocyte Apoptosis via Attenuating Mitochondrial Dysfunction and Increasing Bcl-2 ExpressionPLOS ONE, 2012
- Berberine sensitizes mutliple human cancer cells to the anticancer effects of doxorubicin in vitroOncology Letters, 2012
- Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticalsCancer and Metastasis Reviews, 2010
- Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damageMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009
- p53 cooperates berberine‐induced growth inhibition and apoptosis of non‐small cell human lung cancer cells in vitro and tumor xenograft growth in vivoMolecular Carcinogenesis, 2008
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancerAnnals of Oncology, 2004
- Pharmacokinetics of Pegylated Liposomal DoxorubicinClinical Pharmacokinetics, 2003
- Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinomaCancer, 2001
- Liposome application: problems and prospectsCurrent Opinion in Colloid & Interface Science, 2001